To investigate the clinical prognostic effect of Wenyang Sanjie Decoction（温阳散结汤）combined with immunotherapy on patients of epidermal growth factor receptor（EGFR）mutated advanced non-small cell lung cancer（NSCLC）.

Ninety-three NSCLCpatients with EGFR mutation admitted to the hospital from January 2019 to January 2023 were selected as study subjects，and all patients received the same chemotherapy regimen. Forty patients treated with immune checkpoint inhibitors（ICIs）were selected as the control group，and the other 53 patients treated with Wenyang Sanjie Decoction combined with ICIs were selected as the observation group. Tumor response，tumor markers and quality of life before and after treatment were compared between the two groups. The occurrence of toxic and side effects was compared.

The disease control rate（DCR）and objective response rate（ORR）of the observation group were 98.11% and 66.04%，respectively，and those of the control group were 95.00% and 65.00%，respectively. There was no significant difference in short-term efficacy between the groups（P>0.05）. After treatment，the levels of carbohydrate antigen 125（CA125）and carcinoembryonic antigen（CEA）in both groups were significantly lower than those before treatment（P<0.05），but there was no statistical significance between two groups（P>0.05）. After treatment，the total score of the observation group was significantly lower than that of the control group（P<0.05），and there was no significant difference between the two groups（P>0.05）. The total incidence of toxic and side effects was 32.08% in observation group and 47.50% in control group（P>0.05）.

Wenyang Sanjie Decoction combined with immunotherapy for advanced NSCLCwith EGFR mutation is effective in improving the symptoms of traditional Chinese medicine and has a high safety，suitable for promotion.